A Phase II Trial Involving Patients With Recurrent PCNSL Treated With Carboplatin/BBBD, by Adding Rituxan (Rituximab), An Anti CD-20 Antibody, To The Treatment Regimen.

Trial Profile

A Phase II Trial Involving Patients With Recurrent PCNSL Treated With Carboplatin/BBBD, by Adding Rituxan (Rituximab), An Anti CD-20 Antibody, To The Treatment Regimen.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2017

At a glance

  • Drugs Rituximab (Primary) ; Carboplatin; Cyclophosphamide; Cytarabine; Etoposide; Etoposide phosphate; Filgrastim; Pegfilgrastim; Sodium thiosulfate
  • Indications CNS cancer; Lymphoma; Thrombocytopenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Feb 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 10 Feb 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 02 Jun 2010 Planned end date changed from 1 Jun 2009 to 1 Dec 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top